21
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The inhibition of gut and renal sodium-glucose cotransporters (SGLTs) has been proposed as a novel therapeutic approach to the treatment of diabetes. We have identified dapagliflozin as a potent and selective inhibitor of the renal sodium-glucose cotransporter SGLT2 in vitro and characterized its in vitro and in vivo pharmacology.

          Related collections

          Author and article information

          Journal
          Diabetes
          Diabetes
          American Diabetes Association
          1939-327X
          0012-1797
          Jun 2008
          : 57
          : 6
          Affiliations
          [1 ] Metabolic Diseases Biology, Bristol-Myers Squibb Research and Development, Princeton, New Jersey, USA.
          Article
          db07-1472
          10.2337/db07-1472
          18356408
          db97e342-fc74-4e1b-8ed9-14ecaa2f69b1
          History

          Comments

          Comment on this article